# Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

> **NCT03867201** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 557 (actual)

## Conditions studied

- Migraine

## Interventions

- **BIOLOGICAL:** Erenumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03867201
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-26
- **Primary completion:** 2021-08-11
- **Final completion:** 2024-04-30
- **Target enrollment:** 557 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03867201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03867201, "Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03867201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*